Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AB8939 + azacitidine
- Development stage
- Unknown
- Lead developer
- AB Science
- Modality
- Small Molecules
- Administration
- Intravenous, Subcutaneous, Oral
01
Overview
**AB8939 + azacitidine** is an investigational combination therapy for relapsed or refractory acute myeloid leukemia (AML), particularly evaluated in patients with high-risk, chemotherapy-resistant disease. AB8939 is a next-generation synthetic microtubule destabilizer and a targeted inhibitor of ALDH1A1 and ALDH2, targeting leukemia cancer stem cells and conferring activity against chemoresistant AML subtypes[1][3][5][7]. Azacitidine is a pyrimidine nucleoside analogue and demethylation agent approved for myelodysplastic syndrome (MDS) and AML, acting by incorporating into RNA/DNA and inhibiting DNA methyltransferase, thereby promoting cytotoxicity and hypomethylation[2][4][6]. Preclinical and early trial data suggest synergistic effects of the AB8939 and azacitidine combination, with a significant reduction in leukemia blasts and limited hematotoxicity as compared to standard therapies[1][3][7].
- Brand names
- Azacitidine AccordAzacitidine BetapharmAzacitidine KabiAzacitidine Mylan
- Other names
- AB8939 + azacitidine
02
Targets
ALDH1A1 (Aldehyde dehydrogenase 1 family member A1)ALDH2 (Mitochondrial Aldehyde Dehydrogenase)DNMT1 (DNA (cytosine-5)-methyltransferase 1)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on AB8939 + azacitidine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AB8939 + azacitidine.